Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients

Neoplasma

Volumn 58, Issue 5, 2011, Pages 430-435

  Pluta, P ^a   Cebula Obrzut, B ^a   Ehemann, V ^b   Pluta, A ^a   Wierzbowska, A ^a   Piekarski, J ^a   Bilski, A ^a   Nejc, D ^a   Kordek, R ^a   Robak, T ^a   Smolewski, P ^a   Jeziorski, A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Breast cancer; Flow cytometry; Smac DIABLO protein

Indexed keywords

CASPASE 3; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER CELL; CANCER INFILTRATION; CANCER PATIENT; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; FIBROADENOMA; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CASPASE 3; FEMALE; FIBROADENOMA; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PROGNOSIS; SURVIVAL RATE;

EID: 80052909550     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_05_430     Document Type: Article

References (18)

1. OLOFIN I, OLOPADE OL. Eliminating global disparities in breast cancer care through clinical research. In: ASCO Educational Book. Alexandria, Virginia 2009: 681-684.
2. GOLDHIRSCH A, WOOD WC, GELBER RD, COATES AS, THURLIMANN B et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2007; 18: 1133-1144. doi:10.1093/annonc/mdm271
3. HANAHAN D, WEINBERG RA. The hallmarks of cancer. Cell 2000; 100: 57-70. doi:10.1016/S0092-8674(00)81683-9
4. HEGDE R, SRINIVASULA SM, ZHANG Z, WASSELL R, MUKATTASH R et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277: 432-438. doi:10.1074/jbc.M109721200
5. MARTINS LM, IACCARINO I, TENEV T, GSCHMEISSNER S, TOTTY NF et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002; 277: 439-44.
6. VERHAGEN AM, SILKE J, EKERT PG, PAKUSCH M, KAUFMANN H et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem 2002; 277: 445-454.
7. Leaman DW, Chawla-Sarkar M, VYAS K, REHEMAN M, TAMAI K et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferonstimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002; 277: 28504-11. doi:10.1074/jbc.M204851200
8. YAN N, SHI Y: Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 2005; 21: 35-56. doi:10.1146/annurev.cellbio.21.012704.131040
9. YOO NJ, KIM HS, KIM SY, PARK WS, PARK CH et al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS 2003; 111: 382-388. doi:10.1034/j.1600-0463.2003.t01-1-1110202.x
10. ADRAIN C, CREAGH EM, MARTIN SJ. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 2001; 20: 6627-6636. doi:10.1093/emboj/20.23.6627
11. EHEMANN V, SYKORA J, VERA-DELGADO J, LANGE A, OTTO HF. Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett 2003; 194: 125-131. doi:10.1016/S0304-3835(03)00054-5
12. KEMPKENSTEFFEN C, FRITZSCHE FR, JOHANNSEN M, WEIKERT S, HINZ S et al. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer 2009; 9: 276. doi:10.1186/1471-2407-9-276
13. MIZUTANI Y, NAKANISHI H, YAMAMOTO K, LI YN, MATSUBARA H et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005; 23: 448-454. doi:10.1200/JCO.2005.02.191
14. BAO ST, GUI SQ, LIN MS: Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006; 5: 580-583.
15. Pluta A, Wrzesien-Kus A, CEBULA-OBRZUT B, WOLSKA A, SZMIGIELSKA-KAPLON A et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res. doi:10.1016/j.leukres.2009.11.030, 2010. doi:10.1016/j.leukres.2009.11.030
16. REN Y, AKYUREK N, SCHLETTE E, RASSIDAKIS GZ, MEDEIROS LJ. Expression of Smac/DIABLO in B-cell nonHodgkin and Hodgkin lymphomas. Hum Pathol 2006; 37: 1407-1413. doi:10.1016/j.humpath.2006.06.006
17. ESPINOSA M, CANTU D, LOPEZ CM, DEL LA GARZA JG, Maldonado VA, Melendez-Zajgla J. SMAC is expressed de novo in a subset of cervical cancer tumors. BMC Cancer 2004; 4: 84. doi:10.1186/1471-2407-4-84
18. FREDHOLM H, EAKRER S, FRISELL J, HOLMBERG L, FREDRIKSSON I et al. Breast cancer in young women: poorsurvival despite intensive treatment. PLoS On. doi: 10.1371/journal.pone.0007695,2009.